Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, diminished HFD-induced fatty liver accompanied by a suppression of RAGE and inflammatory cytokines and this effect was reversed by overexpression of NOX2 [301]. The gene discussed is CYBB; the disease is Hepatic steatosis.